The most comprehensive study of its kind showed that psychotic disorders, infections and dementia were among conditions found to be less likely to occur when using GLP-1RAs, which are found in the medications Saxenda, Wegovy and Mounjaro.

The researchers compared health outcomes for people with diabetes who received usual care with those also given drugs such as liraglutide, semaglutide and tirzepatide. While the team revealed the risk of many conditions was lower for the latter group, the risk of other conditions, including arthritic disorders, was increased.

And the scientists say that the benefits are not just restricted to people with diabetes, suggesting they could also be found in other people using the jabs, such as those who take them to fight obesity.